Hinge Health stock
HNGENYSEHinge Health, Inc., HealthcareISIN US4333131039
70Score 70 out of 100, Strong
Price and trend
86 / 100
Price history
+186% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 71% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 1.8% below its 52-week high. Largest decline in 1 year: 49% (August 2025 to February 2026).
Chart figures for advanced users
- SMA 50$103.36
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$70.55
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$31.17
- The lowest closing price of the last twelve months.
- Resistance$123.23
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Hinge Health, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $9.83B, is number 3 of 24 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $587.86M (up 50.6% year on year) and a loss of $528.26M.
- For fiscal 2026, analysts expect on average revenue of $879.41M (up 49.6%) and adjusted earnings per share of $2.52 (up 47.1%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 134 of 702 in Healthcare, median 53.
- Our model puts fair value at $99.39, with the price 22% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 189% of earnings over the last 12 months.Fundamentals 66
- More cash than debtCash $294.66M, financial debt $33.88M.Stability 58
- Analysts expect strong earnings growthUp 25.5% a year through 2028 (estimates from 9 analysts).Growth 50
Weaknesses
- Volatile share priceVolatility 51% a year over the last 12 months.Stability 58
Its standout strengths are momentum and profitability, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $70.99 and expensive above $165.65 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $113.33 (cash-flow model) and $85.45 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $89.63, at 7.8% it would be $114.07.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (44.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 49.9% on the twelve months before. Revenue has grown strongly since 2023, at around 42% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 80%, operating −93%, net −90%. Last 12 months: net 21%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 9 Feb 2027in 88 days
- Last reported
- 2 Nov 2026EPS reported $0.71 (expected $0.58)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 8.6% since 15 Oct 2026.
- Earnings per share
- $2.52+8.6%
- Revenue
- $879.41M+2.2%
- Earnings per share
- $3.13+6.9%
- Revenue
- $1.12B+2.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.0%2026 revenue guidance raised to $856 to $860 million and income from operations to $236 to $244 million (before: $217 to $227 million), with yield around 4.45% versus 4.3%.
“We're also raising our income from operations guidance to $236 million-$244 million, representing a 28% operating margin at the midpoint, up from our prior guidance of $217 million-$227 million or a 27% margin.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $346.76M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Mecklenburg Gabriel M.I.Sale
11 Nov 2026, Board
- Shares
- 200,000
- Price
- $122.41
- Value
- $24.48M
- Budge JamesSale
10 Nov 2026, Chief Financial Officer
- Shares
- 35,907
- Price
- $121.62
- Value
- $4.37M
- Budge JamesSale
12 Oct 2026, Chief Financial Officer
- Shares
- 47,720
- Price
- $103.13
- Value
- $4.92M
Show 25 more
- Mecklenburg Gabriel M.I.Sale
12 Oct 2026, Board
- Shares
- 200,000
- Price
- $103.13
- Value
- $20.63M
- Perez Daniel AntonioSale
6 Oct 2026, 10 percent owner, officer: CEO & Co-Founder
- Shares
- 4,100
- Price
- $100.20
- Value
- $410,811
- Pursley JamesSale
21 Sept 2026, President
- Shares
- 33,000
- Price
- $94.14
- Value
- $3.11M
- Mecklenburg Gabriel M.I.Sale
14 Sept 2026, Board
- Shares
- 150,000
- Price
- $93.22
- Value
- $13.98M
- Mecklenburg Gabriel M.I.Sale
11 Sept 2026, Board
- Shares
- 250,000
- Price
- $88.97
- Value
- $22.24M
- Budge JamesSale
10 Sept 2026, Chief Financial Officer
- Shares
- 55,561
- Price
- $89.45
- Value
- $4.97M
- Perez Daniel AntonioSale
10 Sept 2026, 10 percent owner, officer: CEO & Co-Founder
- Shares
- 250,000
- Price
- $89.45
- Value
- $22.36M
- Pursley JamesSale
21 Aug 2026, President
- Shares
- 33,000
- Price
- $88.05
- Value
- $2.91M
- Leslie Kristina MSale
20 Aug 2026, Board
- Shares
- 1,200
- Price
- $88.23
- Value
- $105,876
- Insight Holdings Group, LLCSale
9 Jul 2026, Major holder
- Shares
- 176,352
- Price
- $90.18
- Value
- $15.9M
- Insight Holdings Group, LLCSale
7 Jul 2026, Major holder
- Shares
- 19,382
- Price
- $90.23
- Value
- $1.75M
- Mecklenburg Gabriel M.I.Sale
1 Jul 2026, Board
- Shares
- 83,334
- Price
- $85.05
- Value
- $7.09M
- Insight Holdings Group, LLCSale
29 Jun 2026, Major holder
- Shares
- 1,466,023
- Price
- $82.83
- Value
- $121.43M
- Insight Holdings Group, LLCSale
25 Jun 2026, Major holder
- Shares
- 499,661
- Price
- $71.74
- Value
- $35.84M
- Insight Holdings Group, LLCSale
24 Jun 2026, Major holder
- Shares
- 23,067
- Price
- $71.67
- Value
- $1.65M
- Insight Holdings Group, LLCSale
24 Jun 2026, Major holder
- Shares
- 242,040
- Price
- $70.84
- Value
- $17.15M
- Insight Holdings Group, LLCSale
23 Jun 2026, Major holder
- Shares
- 8,910
- Price
- $70.21
- Value
- $625,611
- Insight Holdings Group, LLCSale
22 Jun 2026, Major holder
- Shares
- 130,042
- Price
- $70.78
- Value
- $9.2M
- Pursley JamesSale
22 Jun 2026, President
- Shares
- 33,000
- Price
- $69.31
- Value
- $2.29M
- Insight Holdings Group, LLCSale
16 Jun 2026, Major holder
- Shares
- 5,195
- Price
- $70.36
- Value
- $365,518
- Mecklenburg Gabriel M.I.Sale
5 Jun 2026, Board
- Shares
- 50,000
- Price
- $65.54
- Value
- $3.28M
- Budge JamesSale
26 May 2026, Chief Financial Officer
- Shares
- 5,907
- Price
- $53.79
- Value
- $317,757
- Pursley JamesSale
26 May 2026, President
- Shares
- 16,000
- Price
- $53.79
- Value
- $860,606
- Mecklenburg Gabriel M.I.Sale
26 May 2026, Board
- Shares
- 83,333
- Price
- $53.79
- Value
- $4.48M
- Budge JamesSale
20 May 2026, Chief Financial Officer
- Shares
- 781
- Price
- $55.34
- Value
- $43,221
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Hinge Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- BrightSpring Health ServicesBTSG $14.22B66
- Tempus AITEM $13.46B45
- HealthEquityHQY $8.52B71
- M32413.T $7.69B73
- Alibaba Health Information Technology0241.HK $6.02B59
- DoximityDOCS $5.92B82
- Waystar HoldingWAY $5.41B60
- HeartflowHTFL $5.21B47
ETFs that hold Hinge Health
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 4.98% | 0.68% | €5.31M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.18% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.18% | 0.30% | €4.28B |
Show 5 more
| Amundi MSCI Robotics & AI UCITS ETF AccGOAI | 0.10% | 0.40% | €1.17B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.05% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.